Aprea Therapeutics (APRE) - Quarterly EPS earnings growth

Official company branding of Aprea Therapeutics Inc. (APRE)

Aprea Therapeutics (APRE) is accelerating drug synthesis through robotic analysis systems. The GURU.Markets service features a line chart where the quarterly earnings per share trend shows that the metric value is 81.40. Aprea Therapeutics is developing DNA damage inhibitors through clinical alliances and M&A, focusing on early-stage development of targeted drugs to attract major pharmaceutical partners.

Aprea Therapeutics, Inc. (APRE) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/15/2026

Analytical breakdowns for Aprea Therapeutics

- market value and analyst target forecast:
Price Chart Aprea Therapeutics|APRE - Broker Consensus Forecast
- market capitalization indicators:
Market Capitalization Aprea Therapeutics, Inc.|APRE - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Net Assets per Single Share Aprea Therapeutics|APRE - Total Stockholders' Equity|Market Value to Book Value Ratio aprea.com|APRE - Aggregate Company Assets
- debt and liquidity details:
Debt to Equity Aprea Therapeutics|APRE - Long-Term Liabilities to Capital|Short-Term Debt to Capital Aprea Therapeutics Inc.|APRE - Company Total Indebtedness|Debt to Book Value Aprea|APRE - Long-Term Debt|Company Current Liabilities Aprea Therapeutics|Quick Liquidity Indicator aprea.com
- earnings and market multiples details:
APRE - Profit After Payment of Taxes|Projected Future Earnings Aprea Therapeutics|APRE - Company Value to Net Income|Forward P/E Multiple aprea.com|APRE - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aprea Therapeutics, Inc.|APRE - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Aprea Therapeutics|APRE - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months aprea.com|APRE - Earnings per share trend in current year|Expected earnings per share growth for next year Aprea Therapeutics
- sales volume and revenue indicators:
APRE - Company Total Revenue|Projected Sales Volume Aprea Therapeutics, Inc.|APRE - P/S Multiple|Price-to-Projected Revenue Ratio Aprea Therapeutics
Fundamental company analysis:Aprea Therapeutics Inc., APRE
Manufactured product of Aprea Therapeutics

The efficiency of transporting Aprea Therapeutics (APRE) targeted drugs under climate control directly impacts operating expenses, determining the final net profit. This metric measures the percentage change in earnings per share relative to the previous quarter, reflecting the business's profitability dynamics, which allows investors to assess the company's cost resilience and the risk of future drawdowns through quarterly EPS fluctuations.

Analysis of competing companies

Incyte Corporation (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months HUTCHMED Corp|NUVB (nuvationbio.com) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months dayonebio.com (DAWN)|Year-over-year earnings per share growth for the last twelve months Monopar Corp (MNPR)|INBX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months I-Mab Inc. IMAB|Fennec - Year-over-year earnings per share growth for the last twelve months|HRTX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Nuvectis Pharma, Inc.|CHRS: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Corbus Pharma CRBP|Year-over-year net earnings per share growth for the last 12 months CRDF|Earnings per share growth in annualized terms for the last twelve months BeyondSpring Inc. BYSI|Year-over-year net earnings per share growth for the last 12 months BCAB (BioAtla Inc)|LIXT (Lixte Biotechnology Holdings, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Citius Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months CLRB (Cellectar Biosciences, Inc.)|BioLineRx Corp - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months CANF (Can-Fite BioPharma, Ltd.)|KZIA: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Silexion (SLXN)|Year-over-year earnings per share growth for the last twelve months nucana.com|CMRX: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CYCC|Quarterly EPS earnings growth G1 Therapeutics Inc. (GTHX)|Year-over-year earnings per share growth for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Therapeutics, Inc.) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Portage Biotech Inc